EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports

Taketoshi Nara iD, Kengo Furihata, Kazuma Sato, Takuma Sato, Naoko Honma, Yohei Horikawa, Naotake Shimoda

IJU Case Reports · 2026-11 · 9 (6)

DOI: 10.1002/iju5.70291 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IJU Case Reports, online erschienen am 06.11.2026. Verfasst von Taketoshi Nara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Japanese Red Cross Akita Hospital Akita City Japan. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Data on cabozantinib monotherapy for metastatic renal cell carcinoma in patients requiring hemodialysis are scarce. We present two cases: initiation before hemodialysis with subsequent continuation and initiation during maintenance hemodialysis. Case Presentation Case 1 was a 77‐year‐old man with lung metastasis who received cabozantinib after multiple systemic therapies. Cabozantinib was started at 20 mg/day before hemodialysis; hemodialysis began 8 months later, and treatment continued for 59 months with tolerability‐guided schedule modification. Case 2 was a 69‐year‐old man on maintenance hemodialysis who received cabozantinib 20 mg/day for lung and bone metastases. The schedule was changed to alternate‐day dosing. Partial response was achieved, but treatment was discontinued after 4 months because of worsening general condition.

Conclusion

Cabozantinib was administered with individualized dose adjustment and careful monitoring; further clinical and pharmacokinetic data are needed to establish optimal dosing.

Schlagwörter

Stichwörter der Autor:innen

cabozantinibhemodialysismetastatic renal cell carcinomarenal cell carcinomatyrosine kinase inhibitor

Autor:innen und Institutionen

  • Department of Urology Japanese Red Cross Akita Hospital Akita City Japan.
  • Department of Urology Akita University Graduate School of Medicine Akita City Japan.

ORCID-Profile: Taketoshi Nara

Zitieren

APA

Nara, T., Furihata, K., Sato, K., Sato, T., Honma, N., Horikawa, Y., & Shimoda, N. (2026). Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports. IJU Case Reports, 9(6). https://doi.org/10.1002/iju5.70291

Vancouver

Nara T, Furihata K, Sato K, Sato T, Honma N, Horikawa Y, et al. Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports. IJU Case Reports. 2026;9(6). doi:10.1002/iju5.70291

BibTeX
@article{Nara2026,
  author = {Nara, Taketoshi and Furihata, Kengo and Sato, Kazuma and Sato, Takuma and Honma, Naoko and Horikawa, Yohei and Shimoda, Naotake},
  title = {Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports},
  journal = {IJU Case Reports},
  year = {2026},
  volume = {9},
  number = {6},
  doi = {10.1002/iju5.70291}
}
Kostenlos starten →